Table 4

Results of subgroup analyses

SubgroupsStudies, nPatients, nPatients, nEffect estimate Heterogeneity
PERTBaseline or placeboWMD/OR (95% CI)p ValueI2 (%)p Value
PERT vs baseline
CFA
 High-quality studies51721741.78 (0.85 to 2.70)0.000292<0.00001
 Parallel designed51151152.47 (1.42 to 3.52)<0.0000189<0.00001
Multicentre studies41401402.13 (0.84 to 3.43)0.00194<0.00001
 Sample size ≥4041601601.26 (0.51 to 2.00)0.00188<0.00001
 Western population101961971.17 (0.94 to 1.40)<0.0000190<0.00001
FFE
 High-quality studies5172174−1.44 (−2.18 to −0.71)<0.000188<0.00001
 Parallel designed5115117−1.66 (−2.19 to −1.13)<0.0000185<0.00001
 Multicentre studies4140142−1.67 (−2.67 to −0.66)0.00191<0.00001
 Sample size ≥404160162−1.06 (−1.61 to −0.50)0.0002800.002
 Western population12246247−1.70 (−2.29 to −1.12)<0.0000185<0.00001
PERT vs placebo
CFA
 High-quality studies5103941.41 (0.51 to 2.31)0.00286<0.00001
 Parallel designed5107972.03 (0.90 to 3.17)0.000590<0.00001
 Multicentre studies368662.16 (0.85 to 3.48)0.001880.0003
 Sample size ≥40380690.96 (0.28 to 1.64)0.006740.02
 Western population692901.77 (0.68 to 2.86)0.00189<0.00001
FFE
 High-quality studies510394−1.32 (−2.17 to −0.47)0.00285<0.0001
 Parallel designed510797−1.90 (−2.97 to −0.82)0.000590<0.00001
 Multicentre studies36866−2.00 (−3.26 to −0.75)0.002870.0004
 Sample size ≥4038069−0.89 (−1.49 to −0.29)0.004670.05
 Western population69290−1.70 (−2.74 to −0.66)0.00188<0.00001
  • CFA, coefficient of fat absorption; FFE, faecal fat excretion; PERT, pancreatic enzyme replacement therapy; WMD, weighted mean difference.